Wall Street 24/7
Anavex Announces Preparation of Regulatory Filings Based on Guidance From the FDA
Anavex Life Sciences Corp.
NEW YORK, Nov. 18, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, announces that it is moving forward with the development program for ANAVEX 2-73. Guidance received from the FDA confirmsthe Company’s strategy to advance ANAVEX 2-73 for the treatment of Alzheimer’s disease in a larger double-blinded, randomized, placebo-controlled Phase 2/3 trial.
just checked Marketbeat- Good Link- Hav to run post on stocktwits guys
strong buy- just grabbed a bunch